Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target of $93.00. Whitney Ijem has given his Hold rating
Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target of $93.00. Whitney Ijem has given his Hold rating
BioMarin Pharmaceutical announced that positive data from the CANOPY clinical program evaluating VOXZOGO, or vosoritide, in children with achondroplasia and other genetic skeletal conditions will be presented at the 16th
למרות שמחיר היעד הורד, Scotiabank חושבים שהירידה האחרונה במחיר המניה הייתה כנראה יתר על המידה, במיוחד בהתחשב במעמדה של Voxzogo כטיפול אפשרי מוביל לקטנות קומה, האנליסט מודיע למשקיעים.
Scotiabank analyst George Farmer lowered the firm’s price target on BioMarin to $78 from $95 and keeps a Sector Perform rating on the shares. While the firm is lowering its
In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $115.00. The company’s shares